Firm intentionHealthcare16 November 2026

Rosemont Pharmaceuticals Holdings, Inc. to acquire Aytu BioPharma Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Rosemont Pharmaceuticals Holdings, Inc.
Target
Aytu BioPharma Inc.
Deal value
Not disclosed
Announced
16 November 2026
Status
Firm intention
Sector
Healthcare
Country
United States
Consideration
cash
What we know

Aytu BioPharma Inc., a Nasdaq-listed Delaware company, agreed on November 16, 2026 to be acquired by Rosemont Pharmaceuticals Holdings, Inc. The two signed an Agreement and Plan of Merger with RoseApollo Merger Sub, Inc., a wholly owned Rosemont subsidiary. The company issued a press release the same day announcing the agreement. Aytu's board and a special committee of the board unanimously recommended that stockholders accept the offer and tender their shares.

The merger agreement sets the price at $2.70 per share, paid in cash without interest and subject to tax withholding. The filing gives only this per-share price and no aggregate deal value. Unvested options become fully vested immediately before the effective time. Options with an exercise price below the offer price are cashed out for the spread, while those at or above it are cancelled for no consideration, after holders get at least ten days to exercise them. Restricted shares are treated as ordinary shares, with certain employee-held shares paid within set payroll timing. The equity plans and the employee stock purchase plan terminate at the effective time.

The structure is a two-step deal. Within ten business days of signing, the purchaser must start a tender offer for all outstanding shares. Unless extended, the offer expires one minute after 11:59 p.m. New York City time on the twentieth day following and including commencement, as calculated under Rule 14d-1(g)(3). Offer conditions include the tender of a majority of outstanding shares, counting shares already owned by Rosemont, the purchaser and their wholly owned subsidiaries. They also include required third-party consents, payoff letters for outstanding debt and a requirement that no more than 15% of the company warrants, measured by underlying shares, remain outstanding without having been exercised before the offer expires. There is no financing condition. Certain officers, all directors and certain stockholders signed tender and support agreements with Rosemont and the purchaser. They agreed to tender all their shares and to terminate their warrants at the effective time for the consideration in those agreements.

After the purchaser accepts tendered shares, the merger is to be completed under Section 251(h) of the Delaware General Corporation Law, without a stockholder meeting or vote. The purchaser merges into Aytu, which survives as a wholly owned Rosemont subsidiary. Aytu has agreed to non-solicitation restrictions and owes Rosemont a $2.4 million termination fee in specified circumstances, including a switch to a superior proposal or an adverse recommendation change. Either side may terminate if the offer is not completed by February 14, 2027, the 90th day after signing. The offer has not yet commenced, and Rosemont will file a Schedule TO and Aytu a Schedule 14D-9 when it does.

Deal timeline

1 update
  1. Firm intention

    Rosemont Pharmaceuticals Holdings, Inc. firm intention to acquire Aytu BioPharma Inc.

    Item 1.01 Entry into a Material Definitive Agreement. On November 16, 2026, Aytu BioPharma Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Rosemont Pharmaceuticals Holdings, Inc., a Delaware corporation (“Parent”), and RoseApollo Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”). T

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Buyer history

Rosemont Pharmaceuticals Holdings, Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive